SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)

Canagliflozin may increase the risk of toe amputation in patients with type 2 diabetes. Preventive foot care is important for all patients with diabetes, including those receiving a SGLT2 inhibitor (canagliflozin, dapagliflozin, or empagliflozin). Healthcare professionals should carefully monitor patients receiving canagliflozin who have risk factors for amputation and consider stopping treatment with these drugs if foot complications develop. read more

Launch of pilot reporting scheme for harms associated with illicit drugs, particularly new psychoactive substances

Read about a new pilot website for healthcare professionals across the UK to report harms associated with illicit drugs, particularly new psychoactive substances, to us and Public Health England. read more